ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
2 announcements with these filters
Wockhardt reports FY26 revenue of ₹3,373cr with 51% EBITDA growth. Strategy focuses on novel antibiotic 'Zaynich', recently US FDA approved, and diabetes biosimilars to drive future scaling.
Wockhardt FY26 revenue reached INR 3,373 Cr with EBITDA of INR 630 Cr (18.6% margin). Strategy focuses on Novel Antibiotics (Zaynich) and Biosimilars.